On Monday, OSP published a story about AstraZeneca’s latest modeling analysis which highlighted major concerns about the future of chronic kidney disease (CKD) across eight countries.
AstraZeneca's latest modelling analysis, IMPACT CKD, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, paints a concerning picture of the future of chronic kidney disease (CKD) across eight countries.
Medtech startup Metyos has secured €2.3 million in pre-seed funding to advance its mission of improving the lives of chronic kidney disease (CKD) patients worldwide.
Frenova Renal Research has launched its inaugural group of site businesses which comprise F1RST Up – a program designed to accelerate study startup by eliminating common administrative and contracting issues.
CROs are consolidating further, this time with DaVita HealthCare Partners’ business units DaVita Clinical Research (DCR) and HealthCare Partners Clinical Research merging to further expand their services, specifically for patients with chronic kidney...
CRO Covance and Fresenius subsidiary Frenova Renal Research are collaborating to find more effective treatments for patients living with chronic kidney disease (CKD) and end stage renal disease (ESRD).
Amgen will strengthen its drug portfolio aimed at fighting renal
disease after agreeing to acquire Ilypsa, a private biotechnology
company which is developing a novel drug for the treatment of
elevated blood phosphate (hyperphosphataemia)...
US biotech firm Genzyme has been given a green light by the US Food
and Drug Administration (FDA) to begin manufacturing its kidney
drug at its Waterford facility in Ireland.
Ilypsa has completed the first stage of its novel phosphate-binding
agent designed to treat hyperphosphatemia, as the company plough
forward with its pioneering research into next-generation
nonabsorbed polymeric drugs for renal and...
Global medical technology company Gambro has had imports of its
kidney dialysis monitors into the US blocked by the US Food and
Drug Administration (FDA) after a failed plant inspection in
September.
US biotechnology major Genzyme officially opened four European
facilities last week as part of a investment package eventually
expected to cost $540 million (€449m).
The latest data on cases of antibody-mediated pure red cell aplasia
associated with Johnson & Johnson subsidiary Janssen-Cilag's
erythropoietin product Eprex/Erypo (epoetin alfa) have suggested
that measures put in place...
